We conduct translational research in the area of inflammation and immune regulation with a focus on rheumatology, cancer and cardiovascular disease.
Immune-regulated diseases, such as rheumatoid arthritis, are clinically heterogeneous in disease course and response to therapeutic strategies. Clinical variability is likely to result from an interplay of genetic factors with environmental and lifestyle differences.
We are entering the era of ‘precision medicine’ where drug development is moving away from the traditional one-size-fits-all therapeutic approach.
Our priority is to understand the molecular pathways responsible for disease using in vitro models through to identification of biomarkers in groups of patients with a distinct disease phenotype or response to a therapeutic strategy.
Ultimately, linking a molecular pathway or biomarker to a patient group and new sensing techniques will transform our therapeutic approach and the effectiveness of new and emerging medicines.
We have a breadth of expertise in several areas of immune regulation and inflammation including:
- auto-immune and inflammatory disease
- cardiovascular disease
Our skills range from medicinal chemistry through to the impact of lifestyle on treatment.
This area is both interdisciplinary and strongly collaborative with local clinical partners in the Royal National Hospital of Rheumatic Disease (RNHRD) and Royal United Hospital (RUH).
Rheumatology is a strong focus with established links between a team of clinical rheumatologists and the Department of Pharmacy & Pharmacology.
Particular research strengths are in vitro models of inflammation for target identification, RNA biology, new sensor technologies, biomarker identification, pharmaco-epidemiology, and the influence of lifestyle on therapy.